Monoglucosyl rutin, a flavonoid glycoside, improves low-density lipoprotein-cholesterol levels in healthy adults: A randomized controlled trial
DOI:
https://doi.org/10.31989/ffhd.v14i6.1342Abstract
Background: Atherosclerotic cardiovascular disease (ASCVD) continues to be a significant contributor to global mortality, impacting over 523 million individuals worldwide. Dyslipidemia stands as one of the foremost risk factors for ASCVD. Thus, prioritizing the reduction of low-density lipoprotein cholesterol (LDL-C) levels is essential in mitigating cardiovascular complications.
Objective: This study aimed to evaluate the lipid-lowering activity of a dietary supplement containing monoglucosyl rutin (MR) in individuals with low to mild hypercholesterolemia.
Methods: This was a randomized, placebo-controlled, double-blind, parallel-group study conducted from April 20 to December 24, 2022. The study population included 56 healthy Japanese adult participants with LDL-C levels between 120–139 mg/dL who were randomly allocated to either the MR or placebo groups (n = 28/group) using a computerized random number generator. 200 mg of MR or placebo divided into 3 tablets was given daily; participants were instructed to take 1 tablet with water after each meal for 12 weeks. The main focus was on measuring the serum LDL-C level as the primary outcome, with additional attention given to secondary outcomes such as serum high-density lipoprotein cholesterol (HDL-C), total cholesterol, and non-HDL-C levels. The study also evaluated the percentage of participants achieving serum LDL-C levels below 120 mg/dL after the 12-week intervention. Assessments were conducted after 4, 8, and 12 weeks of intervention.
Results: There were 54 (27 in each group) participants in the per-protocol set (PPS) and 53 (placebo group, 26; MR group, 27) participants in the modified PPS (mPPS). A statistically significant group difference in serum LDL-C levels was observed (P < 0.05), with a 5.0% decrease from preintervention to after 12 weeks. The reduction in LDL-C levels coincided with statistically significant decreases in total cholesterol levels, non HDL-C levels, and the LDL-C/HDL-C ratio. During the study period, there was no adverse event or concern about the safety of MR.
Conclusions: MR has potential as a preventive or therapeutic tool for improving improve long-term health and reducing cardiovascular morbidity.
Keywords: monoglucosyl rutin, flavonoid glycoside, low-density lipoprotein cholesterol, hyperlipidemia, lipid profile
Trial registration number: UMIN000047790
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Functional Foods in Health and Disease
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.